In Infectious Disease/Vaccine, News, Phase 1 Clinical Trial

Coronavirus / COVID-19: Updates from WCCT 

[Wednesday, July 1, 2020] 11 weeks after resuming operations at our Cypress, CA clinical pharmacology unit, we are sharing the COVID-19 prevalence data generated at our facility, as well as information regarding the correlation tests performed to confirm the accuracy of our screening platforms.

View the data here.

All COVID-19 testing was performed at our on-site Safety Reference Laboratory. During these uncertain times, WCCT is proud to offer its partners an option to advance their clinical development objectives in a safe and secure setting.

 

[Monday, April 13, 2020] WCCT will be re-opening the clinical trial operations with new COVID-19 testing procedures.  Over the past three weeks, staff at our in-house Safety Reference Laboratory have worked tirelessly in order to source, validate, and launch three highly sophisticated testing platforms and make them available for use at our Orange County-based clinical pharmacology unit. 

 These three tests will allow WCCT medical staff to quickly screen potential study subjects for the virus prior to their participation in a trial. Furthermore, we will enable our partners to continue advancing their pipelines, especially those companies which are currently developing vaccines and anti-viral therapies targeting COVID-19.  

Read the full press release here.

 

[Monday, March 23, 2020] In compliance with CA Governor Gavin Newsom’s statewide shelter-at-home mandate, WCCT will be pausing operations at its facility for the next two weeks, with plans to re-open in early April. Upon re-opening, WCCT expects to have the capability to test for the presence of COVID-19 in-house using its Safety Reference Laboratory, at which point all staff and clinical study volunteers will be tested for the virus.

 

[Thursday, March 19, 2020] In adherence to the recently released FDA guidance on conducting clinical trials amidst the coronavirus outbreak, WCCT has implemented various operational changes at our clinical pharmacology unit in Cypress, CA. We understand more than anything that the situation is fluid and we will be closely monitoring announcements coming from health agencies as well as federal and local government to appropriately adapt our response plan as it pertains to conducting clinical trials at our facility.

Beyond this, as an organization, we would like to join the effort to combat coronavirus in whatever ways possible. We are thankful for the many life science organizations that are shifting their focus or their platforms towards the development of both vaccines and antiviral treatments—we are prepared to do the same.

While we balance the many needs of our partners at this time, we are sensitive to the fact that a solution must be prioritized, and as such our leadership is prepared to discuss projects dedicated towards finding a solution to COVID-19 with urgency.

Now more than ever there is great need for scientific, medical, and operational expertise in the area of infectious disease and vaccine development. When applicable projects come to our doors, we are confident in our ability to execute them in a manner which demonstrates that expertise. If you would like to learn more about our experience in this area, please read more here.

Start typing and press Enter to search